Диссертация (1174315), страница 22
Текст из файла (страница 22)
Looker, A.C. Prevalence of low femoral bone density in older U.S. adultsfrom NHANES III / E.S. Orwoll, C.C. Johnston, R.L. Lindsay [et al.] // J. Bone.Miner. Res.- 1997.- Nov;12(11). P. 1761-1768. PMID: 9383679117. Li, W.F. Genetics of osteoporosis: accelerating pace in gene identificationand validation / S.X. Hou, B. Yu, M.M. Li [et al.] // Hum. Genet.- 2010.- Mar;127(3).- P. 249-285.
doi: 10.1007/s00439-009-0773-z118. Liu, Z.Y. Serum Osteocalcin and Testosterone Concentrations in AdultMales with or without Primary Osteoporosis: A Meta-Analysis / Y. Yang, C.Y.Wen, L.M. Rong // Biomed. Res. Int.- 2017.-P. 1-7. DOI: 10.1155/2017/9892048119. Lu, C. Response to teriparatide in Chinese patients with establishedosteoporosis: osteocalcin and lumbar spine bone-mineral density changes fromteriparatide Phase III study / Y. Chen, B. Zhang, Y. Chen [et al.] // Clin. Interv.Aging.- 2017.- Oct 12;12.- P. 1717-1723. DOI: 10.2147/CIA.S140900120.
Mariola, J. Men's knowledge about osteoporosis and its risk factors / D.Żołnierczuk-Kieliszek, T. Kulik, M.A. Dziedzic [et al.] // Prz. Menopauzalny.2016.- Nov;15(3).- P. 148-155.121. Marcus, R. The relationship of biochemical markers of bone turnover tobone changes in postmenopausal women: results from the PEPI trial / L. Holloway,B. Wells, G. Greendale [et al.] // J. Bone. Miner. Res.- 1999.- Sep;14(9). P.
15831595.131122. Meddah, B. Urinary excretion of free and total deoxypyridinoline duringsecondary hyperparathyroidism in the elderly. Comparison of chromatographic(HPLC) and immunoenzymatic (Pyrilinks-D) methods / M. Brazier, S. Kamel, M.Maamer [et al.] // Ann. Biol. Clin. (Paris).- 1996.-54(10-11).- P. 353-358.123. Melton, L.J. Relationship of bone turnover to bone density and fractures /S. Khosla, E.J.
Atkinsтon, W.M. O’Fallon [et al.] // J. Bone. Miner. Res.- 1997.12(7).- P. 1083-1091. DOI: 10.1359/jbmr.1997.12.7.1083124. Meier, C. Osteoporosis drug treatment: duration and management afterdiscontinuation. A position statement from the SVGO/ASCO / B. Uebelhart, B.Aubry-Rozier, M. Birkhäuser [et al.] // Swiss.
Med. Wkly.- 2017.- Aug 16.- 6 p.125. Meurs, v.J.B. Common genetic variation of the low-density lipoproteinreceptor-related protein 5 and 6 genes determines fracture risk in elderly white men/ F. Rivadeneira, M. Jhamai, W. Hugens [et al.] // J. Bone. Miner. Res.- 2006.№1.- T.21.- P. 141-150.126. Michel, L. Heterogeneity of biological bone markers in Idiopathic MaleOsteoporosis // Rheumatol.
Int.- 2012.- Jul; 32(7).- 2101-2104.127. Mitsunobu, F. Complexity of terminal airspace geometry assessed bycomputed tomography in asthma / K. Ashida, Y. Hosaki, H. Tsugeno [et al.] // Am.J. Respir. Crit. Care. Med.- 2003.- Feb 1;167(3).- P. 411-417.128. Mode, C.J.
On statistical tests of significance in studies of survivorship inlaboratory animals / R.D. Ashleigh, A. Zawodniak, G.T. Baker [et al.] // J.Gerontol.- 1984.- №1.- Т.39.- P. 36-42.129. Morrison, N.A. Prediction of bone density from vitamin D receptor alleles /J.C. Qi, A. Tokita, P.J. Kelly [et al.] // Nature.- 1994.- №6460.- Т.367.- P. 284-87.130. Muhlen, D.
Associations between the metabolic syndrome and bone healthin older men and women: the Rancho Bernardo Study / S. Safii, S.K. Jassal, J.Svartberg [et al.] // Osteoporos. Int.- 2007.- Oct; 18(10).- P. 1337-1344.131. Muruganandan, S. The impact of bone marrow adipocytes on osteoblastand osteoclast differentiation / C.J. Sinal // IUBMB. Life.- 2014.- Is.3.- P.
147-155.132132. Nakamura, Y. Alfacalcidol Increases the Therapeutic Efficacy ofIbandronate on Bone Mineral Density in Japanese Women with PrimaryOsteoporosis / T. Suzuki, M. Kamimura, S. Ikegami [et al.] // Tohoku. J. Exp.Med.- 2017.- Apr;241(4).- P.319-326. doi: 10.1620/tjem.241.319133.
NIH, Consensus. Development Panel on Osteoporosis Prevention,Diagnosis, and Therapy // Osteoporosis prevention, diagnosis, and therapy.JAMA.- 2001.- Feb 14;285(6).- P. 785-795.134. Nishikawa, K. Maf promotes osteoblast differentiation in mice bymediating the age-related switch in mesenchymal cell differentiation / T.Nakashima, S. Takeda, M. Isogai [et al.] // J. Clin. Invest.- 2010.- №10.- Т.120.- P.3455-3465.135. Nuti, R. Superiority of alfacalcidol compared to vitamin D plus calcium inlumbar bone mineral density in postmenopausal osteoporosis / G.
Bianchi, M.L.Brandi, R. Caudarella [et al.] // Rheumatol. Int.- 2006.- Mar; 26(5).- P. 445-453.136. Orwoll, E.S. Osteoporosis in men / R.F. Klein // Endocr. Rev.- 1995.- Feb;16(1).- P. 87-116. DOI: 10.1210/edrv-16-1-87137. Orwoll, E. Alendronate for the treatment of osteoporosis in men / M.Ettinger, S. Weiss, P.
Miller [et al.] // N. Engl. J. Med.- 2000.-. №9.- Т.343.- P.604-610.138. Orwoll, E.S. Efficacy and safety of monthly ibandronate in men with lowbone density / N.C. Binkley, E.M. Lewiecki, U. Gruntmanis [et al.] // Bone.2010.- №4.- Т.46.- P. 970-976.139. Orwoll, E.S.
Efficacy and safety of a once-yearly i.v. Infusion of zoledronicacid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of maleosteoporosis: a randomized, multicenter, double-blind, active-controlled study /P.D. Miller, J.D. Adachi, J. Brown [et al.] // J. Bone. Miner. Res.- 2010.- №10.Т.25.- P.
2239-2250.140. Ohgitani, S. Calcium decreases urinary oxalate / T. Fujita // Article inJapanese Nihon Ronen Igakkai Zasshi.- 2000.- Oct; 37(10).- P. 805-810.133141. Patsch, J.M. Trabecular bone microstructure and local gene expression iniliac crest biopsies of men with idiopathic osteoporosis / T. Kohler, A.Berzlanovich, C. Muschitz [et al.] // J.
Bone. Miner. Res.- 2011.- Jul;26(7).- P.1584-1592. doi: 10.1002/jbmr.344 PMID: 21308775142. Pierre, H. Bone Marrow Adipose Tissue: To Be or Not To Be a TypicalAdipose Tissue? / R. Tareck, L. Stéphanie // Front. Endocrinol. (Lausanne).2016.- P. 1-11.143. Premaor, M.O. Obesity and fractures in postmenopausal women / L.Pilbrow, C.
Tonkin, R.A. Parker [et al.] // J. Bone. Miner. Res.- 2010.- Feb; 25(2).P. 292-297.144. Pye, S.R. Bone turnover predicts change in volumetric bone density andbone geometry at the radius in men / K.A. Ward, M.J. Cook, M.R. Laurent [et al.]// Osteoporos. Int.- 2017.- Mar;28(3).- P. 935-944.145. Reginster, J.Y. Osteoporosis: A still increasing prevalence / N.Burlet //Bone.- 2006.- №2.- Т.38.- P.
4-9. DOI: 10.1016/j.bone.2005.11.024146. Reginster, J.Y. Importance of alfacalcidol in clinical conditionscharacterized by high rate of bone loss / M.P. Lecart, F. Richy // J. Rheumatol.Suppl.- 2005.- Sep; 76.- P. 21-25.147. Richy, F. Efficacy of alphacalcidol and calcitriol in primary andcorticosteroid-induced osteoporosis: a meta-analysis of their effects on bonemineral density and fracture rate / O. Ethgen, O. Bruyere, J.Y. Reginster //Osteoporos.
Int.- 2004.- Apr; 15(4).- P. 301-310.148. Riggs, B.L. A population-based assessment of rates of bone loss at multipleskeletal sites: evidence for substantial trabecular bone loss in young adult womenand men / L.J. Melton, R.A. Robb, J.J. Camp [et al.] // J. Bone. Miner. Res.- 2008.№2.- Т.23.- P. 205-214.149. Ringe, J.D. Efficacy of risedronate in men with primary and secondaryosteoporosis: results of a 1-year study / H. Faber, P. Farahmand, A.
DorstRheumatol. Int.- 2006.- Mar;26(5).- P. 427-431. DOI: 10.1007/s00296-005-0004-4134150. Ringe, J.D. Three-monthly ibandronate bolus injection offers favourabletolerability and sustained efficacy advantage over two years in establishedcorticosteroid-induced osteoporosis / A. Dorst, H. Faber, K. Ibach [et al.] //Rheumatology. (Oxford).- 2003.- Jun;42(6).- P. 743-749.151.
Ringe, J.D. Prevention and therapy of osteoporosis: the roles of plainvitamin D and alfacalcidol / E. Schacht // Rheumatol. Int.- 2004.- Jul; 24(4).- P.189-197.152.Robins,S.P.Direct,enzyme-linkedimmunoassayforurinarydeoxypyridinoline as a specific marker for measuring bone resorption / H. Woitge,R. Hesley, J. Ju [et al.] // J.
Bone. Miner. Res.- 1994.- Oct;9(10).- P. 1643-1649.153. Roholl, P.J. Evidence for a diminished maturation of preosteoblasts intoosteoblasts during aging in rats: an ultrastructural analysis / E. Blauw, C. Zurcher,J.A. Dormans [et al.] // J. Bone. Miner. Res.- 1994.- №3.- Т.9.- P. 355-366.154. Roux, C. New insights into the role of vitamin D and calcium inosteoporosis management: an expert roundtable discussion / H.A. B-Ferrari, S.E.Papapoulos, A.E. Papp [et al.] // Curr. Med. Res. Opin.- 2008.- №5.- Т.24.- P.1363-1370.155. Saito, M. Biochemical markers of bone turnover. New aspect.
Bonecollagen metabolism: new biological markers for estimation of bone quality // Clin.Calcium.- 2009.- Aug;19(8).- P. 1110-1117. doi: CliCa090811101117156. Scane, AC. Case-control study of the pathogenesis and sequelae ofsymptomatic vertebral fractures in men / R.M. Francis, A.M. Sutcliffe, M.J.Francis [et al.] // Osteoporos. Int.- 1999.- 9(1).- P. 91-97.157. Schuit, S.C.
Fracture incidence and association with bone mineral densityin elderly men and women: the Rotterdam Study / M. Klift, A.E. Weel, C.E. Laet[et al.] // Bone.- 2004.- №1.- Т.34.- P. 195-202. PMID: 14751578158. Schwarz, P. Status of drug development for the prevention and treatment ofosteoporosis/N.R. Jørgensen, B. Abrahamsen // Expert. Opin. Drug. Discov.-2014.- Mar;9(3).- P. 245-253.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
